πŸ‡ΊπŸ‡Έ FDA
Patent

US 11266649

Pharmaceutical formulations

granted A61KA61K31/519A61K47/02

Quick answer

US patent 11266649 (Pharmaceutical formulations) held by Corvus Pharmaceuticals, Inc. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corvus Pharmaceuticals, Inc.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/519, A61K47/02, A61K47/14, A61K47/26